Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 55% of resolved cases
Sydney Van Druff is an examiner in Tech Center 1600 and Art Unit 1643, where she has handled 149 resolved cases. Her allowance rate is 55.0%, which indicates a balanced but rigorous examination style. This 55.0% rate serves as a baseline for applicants to gauge their chances of success in this art unit. The 149 cases resolved by this examiner provide a consistent look at her typical prosecution outcomes.
The median days to allowance for this examiner is 1154, reflecting a standard prosecution timeline. Additionally, the data shows an interview lift of 31.7%, which provides a significant boost to the probability of success. This positive lift suggests that direct communication can be a very effective tool for resolving outstanding issues and moving toward an allowance. The 1154-day median pendency is a key data point for practitioners to use in their strategic planning.
For those in Art Unit 1643, the combination of a 55.0% allowance rate and a 31.7% interview lift suggests that active advocacy is essential. The 149 resolved cases demonstrate a pattern where interviews can significantly improve the odds of a grant. Utilizing interviews to supplement written responses may help navigate the examiner's review process more effectively. This data-driven profile supports a proactive approach to prosecution in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18590729 | SELECTIVE REDUCTION OF ANTIBODIES | Non-Final OA | AbbVie Inc. |
| 18156744 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Final Rejection | Genentech, Inc. |
| 17775198 | IDENTIFICATION OF SPLICING-DERIVED ANTIGENS FOR TREATING CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18044405 | GALACTOSYLATED DENDRIMERS FOR TARGETED INTRACELLULAR DELIVERY TO HEPATOCYTES | Non-Final OA | The Johns Hopkins University |
| 17920461 | DUOCARMYCIN DERIVATIVE AND USE THEREOF | Final Rejection | TOHOKU UNIVERSITY |
| 17612280 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Final Rejection | Novartis AG |
| 17054312 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | Final Rejection | William Marsh Rice University |
| 18261456 | FORMULATIONS AND METHODS FOR MHC-I RESTRICTED EPITOPE IMMUNIZATION | Non-Final OA | The Research Foundation for The State University of New York |
| 18042958 | Nucleic Acid-Derivatized Therapeutics | Final Rejection | The University of Chicago |
| 17984169 | COMPOSITIONS AND METHODS OF USE OF GENETICALLY MODIFIED IMMUNE CELLS EXPRESSING MATRIX METALLOPEPTIDASE | Non-Final OA | University of Houston System |
| 17290797 | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE | Final Rejection | Thomas Jefferson University |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | Final Rejection | MedImmune, LLC |
| 17262590 | EFFECTIVE METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 18681163 | ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND USE IN CONGENITAL ADRENAL HYPERPLASIA | Non-Final OA | HBM ALPHA THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy